Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.4121
$0.053114.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 344.64% | -23.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 175.49% | -16.42% | |||
| Operating Income | -175.49% | 16.03% | |||
| Income Before Tax | 95.64% | 14.26% | |||
| Income Tax Expenses | -- | 668.57% | |||
| Earnings from Continuing Operations | 97.35% | -55.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 97.35% | -55.95% | |||
| EBIT | -175.49% | 16.03% | |||
| EBITDA | -175.56% | 16.04% | |||
| EPS Basic | 99.99% | 63.68% | |||
| Normalized Basic EPS | 99.24% | 80.03% | |||
| EPS Diluted | 99.99% | 63.68% | |||
| Normalized Diluted EPS | 99.24% | 80.03% | |||
| Average Basic Shares Outstanding | 35,789.98% | 329.52% | |||
| Average Diluted Shares Outstanding | 35,789.98% | 329.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||